Cargando…

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients

Detalles Bibliográficos
Autores principales:	Patelli, Giorgio, Pani, Arianna, Amatu, Alessio, Scaglione, Francesco, Sartore-Bianchi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920783/ https://www.ncbi.nlm.nih.gov/pubmed/35370047 http://dx.doi.org/10.1016/j.ejca.2022.02.032

Ejemplares similares

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment
por: Amatu, Alessio, et al.
Publicado: (2022)

Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS‐CoV‐2 vaccine
por: Xu, Xingli, et al.
Publicado: (2022)

Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors
por: Pietroluongo, Erica, et al.
Publicado: (2023)

Seroconversion after Inactive SARS-CoV-2 Vaccination and Obesity: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Symptomatic SARS-CoV-2 breakthrough with delta variant after 3rd mRNA vaccine shot (booster)
por: Schildgen, Verena, et al.
Publicado: (2022)

Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

SARS-CoV-2 vaccination improves HBV seroconversion rate through heterological immunity
por: Anft, Moritz, et al.
Publicado: (2023)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
por: Healy, Katie, et al.
Publicado: (2022)

Passive inhaled mRNA vaccination for SARS-Cov-2
por: Yeo, Wee Song, et al.
Publicado: (2021)

Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine
por: Belda, Francisco, et al.
Publicado: (2022)

Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
por: Benucci, Maurizio, et al.
Publicado: (2022)

Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination
por: Langerak, T., et al.
Publicado: (2022)

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster
por: da Silva, Almir Ribeiro, et al.
Publicado: (2022)

Ramsay Hunt syndrome and mRNA SARS-COV-2 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Ramsay Hunt syndrome and mRNA SARS-COV-2 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
por: Kuhlmann, Constanze, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
por: Nanishi, Etsuro, et al.
Publicado: (2022)

Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2022)

New-onset MOGAD after first-dose SARS-CoV-2 mRNA vaccination with relapse following SARS-CoV-2 mRNA booster
por: Arismendez, Alan A., et al.
Publicado: (2023)

Ramsay Hunt syndrome following mRNA SARS-COV-2 vaccine()
por: Rodríguez-Martín, Minerva, et al.
Publicado: (2022)

Note for “Ramsay Hunt syndrome and mRNA SARS-COV-2 vaccination”()
por: Rodríguez-Martín, Minerva
Publicado: (2022)

Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Corrigendum: Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2023)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Seroconversion after COVID-19 vaccine in a dialysis patient on immunosuppressants
por: Alfano, Gaetano, et al.
Publicado: (2021)

Sustained humoral response 6 months after the anti-SARS-CoV-2 mRNA-BNT162b2 vaccine in haemodialysis patients: should booster vaccine doses be given to all patients at the same time?
por: La Milia, Vincenzo, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
por: Zhang, Biyan, et al.
Publicado: (2022)

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
por: Marasco, Vincenzo, et al.
Publicado: (2021)

381 Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals
por: Piros, É.A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qqp1n1h390ql5iha5hhtdtff1f